Clinical Trial Design and Interpretation

Clinical trial design and interpretation concerns how trials of medicines are structured to yield unbiased estimates of effect and how their results should be read. Randomisation, blinding, an adequate sample size, and a pre-specified analysis are the design features that make a trial's answer trustworthy, and understanding them is essential to interpreting the literature on drug efficacy and safety.

Definition

A clinical trial is a prospective study that assigns participants to interventions, ideally by randomisation, to estimate the effect of a treatment; its design and analysis determine how free the resulting effect estimate is from bias and chance.

Scope

This topic covers the architecture of controlled trials — randomisation, allocation concealment, blinding, control choice, and outcome definition — and the interpretation of their results, including effect estimates, confidence intervals, intention-to-treat analysis, and superiority versus non-inferiority framing. It is a methodological and reference topic, not a guide to prescribing.

Core questions

• How do randomisation, allocation concealment, and blinding protect a trial from bias?
• What does the comparator and outcome choice imply for interpretation?
• How are effect size and precision read from estimates and confidence intervals?
• How do intention-to-treat analysis and pre-specification guard validity?
• What distinguishes superiority, non-inferiority, and equivalence designs?

Key concepts

• Randomisation and allocation concealment
• Blinding (masking)
• Comparator and outcome selection
• Intention-to-treat analysis
• Pre-specified statistical analysis plan
• Confidence intervals and effect estimates
• Superiority versus non-inferiority designs

Mechanisms

Randomisation distributes known and unknown confounders evenly between groups, and allocation concealment plus blinding prevent the assignment from influencing recruitment, care, or outcome assessment. A pre-specified statistical analysis plan, fixed before unblinding, protects against data-driven choices, and intention-to-treat analysis preserves the benefit of randomisation by analysing participants in their assigned groups. Results are read as an effect estimate with a confidence interval expressing precision. The interpretive frame matters: a superiority trial asks whether a treatment is better, whereas a non-inferiority trial asks whether it is not unacceptably worse within a pre-defined margin, a design that — as Mauri and D'Agostino emphasise — is easy to misread. The CONSORT statement standardises how all of these features are reported, and risk-of-bias tools such as RoB 2 assess whether they were upheld.

Clinical relevance

Reading trials critically underlies decisions about which medicines work, for whom, and how safely, and it shapes formulary and guideline judgements. This topic describes how trial evidence is generated and interpreted and supports its appraisal; it is not a source of individualised treatment decisions.

Evidence & guidelines

Trial conduct and reporting are governed by widely endorsed standards: the CONSORT 2010 statement for reporting parallel-group randomised trials, guidance on the content of statistical analysis plans, and the Cochrane RoB 2 tool for assessing risk of bias. These are maintained by their developer groups and periodically updated.

History

The controlled trial was placed on a modern footing by the British Medical Research Council's randomised streptomycin trial for tuberculosis in the late 1940s, which is widely regarded as a landmark in trial methodology. Over subsequent decades randomisation, blinding, and intention-to-treat analysis became standard, and from the 1990s reporting standards such as CONSORT and structured risk-of-bias assessment formalised how trials are described and appraised.

Debates

How should non-inferiority trials be designed and interpreted?

Non-inferiority trials hinge on a pre-specified margin and on assay sensitivity; a poorly chosen margin or a low-quality trial can make an inferior treatment appear acceptable, so these designs require careful interpretation.

Key figures

• Kenneth Schulz
• Douglas Altman
• David Moher
• Laura Mauri

Seminal works

• schulz-2010-consort
• mauri-2017
• sterne-2019-rob2

Frequently asked questions

Why is intention-to-treat analysis preferred?

Analysing participants in the groups to which they were randomised preserves the comparability that randomisation created; excluding non-adherers can reintroduce the bias randomisation was meant to remove.

What does a non-inferiority trial actually test?

It tests whether a new treatment is not worse than a comparator by more than a pre-specified margin, rather than whether it is better; interpreting it correctly depends on that margin being clinically justified.